http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2437700-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d53094985a54e1cafd22f23d76be4007 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7158 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-715 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 |
| filingDate | 2002-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c668f03323fe640443a09ab354d7d7b8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f098f73345f7f60be8a7b68f8d55cd8 |
| publicationDate | 2002-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2437700-A1 |
| titleOfInvention | Regulation of cc chemokine receptor 3 (ccr3) expression |
| abstract | A method of regulating CCR3 expression by transcriptional and mRNA control. In one embodiment, regulation ossurs in a non-promoter, regulatory region of the CCR3 gene, such as untranslated exons 1, 2, and/or 3. This type of regulation has a preferential effect on eosinophilic cells; such selectivity advantageously produces less deleterious side effects when administered in a pharmaceutical prepearation. Regeulation of CCR3 expression by promoter targeting also presents a method to reduce CCR3 expression in a cell-specific or nonspecific manner. Other types of regulatory compounds do not semonstrate such a prefential effect. Because CCR3 is expressed on cells involved in inflammatory reactions, regulations of CCR3 provides an intervention site for asthma, as well as other allergic, inflammatory and hypersensitivity reactions, eosinophil-mediated diseases, and infectious disorders. |
| priorityDate | 2001-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 154.